Laboratory Procedure – Page 2

Trump Locks in 15% Pharmaceutical Tariff Rate for EU, Generic Drugs Exempted

2 months ago talkbio0Tagged 15%, brand-name drugs, EU, Evaluation, Generic Drugs, Sectioning technique, tariff, tariff exemption, TNFRSF19 gene, transatlantic trade, Trump administration

15% tariff; pharmaceuticals; EU; Trump administration; generic drugs; trade deal; tariff exemption; brand-name drugs; transatlantic trade; Section 232 investigation

Trump Announces Massive Pharma Tariffs Up to 250%, Signals Enforcement Within Days

3 months ago talkbio0Tagged Biopharma, Canada, fentanyl crisis, international trade, Pharma Tariffs, Sectioning technique, tariff increase, Transplant Registry Unified Management Program

Trump; pharma tariffs; tariff increase; biopharma; Canada; Section 301; international trade; fentanyl crisis

Lilly’s Mounjaro Matches Cardiovascular Benefit of Trulicity in Landmark Trial, Paving Way for Expanded Approval

3 months ago talkbio0Tagged Cardiovascular system, Diabetes Mellitus, Non-Insulin-Dependent, dulaglutide, eli lilly, expansion, Hemoglobin A1c measurement, MACE-3, Mortality Vital Statistics, Mounjaro, non-inferiority, outcomes, SURPASS-CVOT, Trulicity, United States Food and Drug Administration, Weight Loss

Mounjaro; tirzepatide; Eli Lilly; cardiovascular outcomes; type 2 diabetes; SURPASS-CVOT; Trulicity; dulaglutide; major adverse cardiovascular events (MACE-3); non-inferiority; A1C reduction; weight loss; mortality; FDA expansion

Trump’s Pharmaceutical Tariffs Materialize in New US-EU Trade Deal

3 months ago talkbio0Tagged 15%, European (ethnic group), Evaluation, pharmaceutical tariffs, Sectioning technique, tariff, trade agreement, Transplant Registry Unified Management Program, U.S., Union, US-EU

Trump; pharmaceutical tariffs; US-EU trade deal; 15% tariff; Section 232 investigation; European Union exports; trade agreement

CorestemChemon Partners with ATG Lifetech to Expand Organoid and Transcriptomics Capabilities

3 months ago talkbio0Tagged Blood - brain barrier anatomy, CorestemChemon, Drug Discovery, FDA/EMA regulatory pathways, Gene Expression Profiling, heart organoids, Lifetech, liver organoids, lymphocyte immune globulin, anti-thymocyte globulin, Organoids, preclinical CRO, Predictive analytics, Tumorigenicity

CorestemChemon; ATG Lifetech; organoids; transcriptomics; preclinical CRO; drug discovery; predictive analytics; tumorigenicity; FDA/EMA regulatory pathways; liver organoids; heart organoids; blood-brain barrier models

Organoid Startup Raises $21M to Test Drugs and Vaccines in Human Lymph Nodes-in-a-Dish

5 months ago talkbio0Tagged biotech startup, Homo sapiens, lymph nodes, Organoids, research funding, Substance Abuse Detection, tissue models, Vaccine Testing

organoids; lymph nodes; drug testing; vaccine testing; biotech startup; research funding; human tissue models

FDA Places Clinical Hold on Five Gilead HIV Studies Due to Safety Concerns

5 months ago talkbio0Tagged Biktarvy, CD4 + T-cell, Clinical Trials, Gilead Sciences, GS-1720, GS-4182, HIV, Lenacapavir, Lymphocyte Count measurement, safety signal, Study on Hold, United States Food and Drug Administration

FDA; Gilead Sciences; HIV; clinical hold; GS-1720; GS-4182; clinical trials; safety signal; CD4+ T-cell; lymphocyte count; Biktarvy; lenacapavir

Regeneron to Acquire 23andMe Out of Bankruptcy for $256 Million

5 months ago talkbio0Tagged Acquisition, Bankruptcy, data privacy, Genetic testing for cancer risk, Genome, personal genome service, Purchased Services, Clinical and Biomedical, Research, Regeneron, total health

Regeneron; 23andMe; acquisition; bankruptcy; genetic testing; genome; personal genome service; total health; research services; data privacy

Leqembi’s Expansion and Blood Test Impact: Analyst Sees Gradual Uptake Boost

5 months ago talkbio0Tagged Adoption, Alzheimer 's disease, Approved, AutoInjector, Biogen, dosing, Eisai, Hematologic Tests, launch, Leqembi, Maintenance, Market, subcutaneous, United States Food and Drug Administration

Leqembi; Eisai; Biogen; Alzheimer’s disease; FDA approval; blood test; launch; maintenance dosing; autoinjector; subcutaneous; market adoption

Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies

6 months ago talkbio0Tagged Administration occupational activities, Albert, Bourla, chain concerns, Evaluation, Investments, Manufacturing, National Security, pharmaceutical tariffs, Policy, Sectioning technique, TNFRSF19 gene, Transplant Registry Unified Management Program

Pharmaceutical tariffs, Section 232 investigation, Albert Bourla, national security, trade policy, manufacturing investments, Trump administration, supply chain concerns